Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.
Diversity Hemex Team
Meet Brandon García, our newest intern at HEMEX
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue reading
Investment Press Release
Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Clinical Development Innovation Investment Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study
Continue reading
Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue readingDiversity Hemex Team Innovation
Empowering our people, transforming our world in 2023
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue readingClinical Development, Innovation, Investment, Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study
Innovation, Investment, Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.
Innovation, Investment, Press Release
Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
